《港樓》新地(00016.HK)天璽-天第2期料9月中先推四房戶招標
新地(00016.HK)旗下的啟德天璽-天第2期,共涉584伙,預計9月中旬先推出四房戶招標。新地代理總經理胡致遠指出,天璽-天第2期屬於該發展項目的第1座及第2座,分成三大區域,分別為Elite Zone、Sky Tower及Summit Tower,首階段先推出四房戶招標,包括第1座高層A室及B室。他補充,天璽.天第1期四房戶呎價最高達4.5萬元,第2期有望挑戰新高。
新地副董事總經理雷霆指出,天璽-天第1期於大半年前推出,約一個月吸金約110億元,交樓程序接近完成。他提到,美國聯儲局有望連環減息;加上新盤庫存持續減少,今年第四季成交量及價錢有望同步上升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.